ECL

Ecolab

$294.70

-0.88%
Nov 20, 2026
Bobby Quantitative Model
Ecolab is the global leader in water, hygiene, and infection-prevention products and services, serving industrial manufacturing, data centers, hospitality, healthcare, life sciences, and foodservice customers through a portfolio spanning dish and laundry systems, pest elimination, water management and cooling solutions, and bioprocessing consumables. Its competitive identity rests on a service-intensive, razor-to-razor business model with deep customer entrenchment, scale advantages, and a global field-service footprint of roughly 48,000 employees that few specialty-chemical peers can replicate. The current investor narrative centers on Ecolab's strategic pivot toward higher-margin, higher-growth adjacencies — notably AI data-center liquid cooling following the $4.75 billion CoolIT acquisition and bioprocessing for life sciences — which management and sell-side analysts argue is accelerating growth and margin expansion even as softer restaurant/foodservice traffic creates a near-term headwind. That tension between structural growth optionality and cyclical end-market softness, layered on a premium valuation, is the core debate driving the stock.

People also watch

Sherwin-Williams

Sherwin-Williams

SHW

Analysis
Air Products & Chemicals

Air Products & Chemicals

APD

Analysis
PPG Industries

PPG Industries

PPG

Analysis
International Flavors & Fragrances

International Flavors & Fragrances

IFF

Analysis
LyondellBasell

LyondellBasell

LYB

Analysis

BobbyInvestment Opinion: Should I buy ECL Today?

Rating: Hold (constructive, quality-at-a-fair-price). Ecolab is a best-in-class water, hygiene, and infection-prevention franchise whose 12.72% YoY Q3 revenue growth, 196bp operating-margin expansion from Q1 (15.30%) to Q3 (17.26%), and $1.795B TTM free cash flow justify a premium multiple, but at $309.27 the stock already trades at 35.8x trailing and 32.9x forward earnings with only +6.9% implied upside to the $330.57 average target, so the risk/reward is balanced rather than compelling. The 20 Buy/4 Hold/0 Sell consensus (recommendation mean 1.54) confirms the quality of the franchise but not a mispricing opportunity at current levels.

Supporting evidence is strong on fundamentals: revenue re-accelerated to $4.695B in Q3 2026 from $4.165B a year earlier (+12.72%), operating margin stepped up from 15.30% in Q1 to 17.26% in Q3 while gross margin held in a stable 43.5%–44.1% band, and ROE of 21.24% versus a specialty-chemical sector norm in the mid-single-to-low-double digits supports the quality premium. Free cash flow of $1.795B comfortably covers the $204.6M quarterly dividend (36.3% payout, 1.01% yield), and the stock has delivered +22.77 points of six-month relative strength versus SPY. The offset is valuation: 35.8x trailing PE, 24.0x EV/EBITDA, 5.76x EV/Sales, and 7.61x price-to-book represent roughly a 50–70% premium to specialty-chemical peers in the high-teens to low-20s PE range, and the $300 low analyst target sits below the current price.

Three risks could invalidate the thesis: CoolIT integration friction on a $4.75B deal that drove a $4.413B net cash decline and lifted debt-to-equity to 0.965 with a thin 1.076 current ratio; further deterioration in restaurant/foodservice traffic hitting the $1.638B Global Institutional segment; and multiple compression from 35.8x toward the low-30s historical median if growth decelerates toward mid-single digits. This Hold would upgrade to Buy on a pullback toward the $280s (roughly 30x forward EPS of $12.88) or on evidence of sustained high-teens operating margins with organic growth above 8%, and would downgrade to Sell if organic growth fell below 5% or CoolIT integration slipped. Verdict: fairly valued to modestly rich relative to both its own history and peers — a premium compounder priced as such, not a bargain.

Sign up to view all

ECL 12-Month Price Forecast

Ecolab's fundamentals are unambiguously strong — double-digit revenue growth, expanding operating margins, $1.795B of TTM free cash flow, and a 21.24% ROE — but the stock at $309.27 already discounts much of that quality at 35.8x trailing earnings. The analyst community is aligned on the franchise (20 Buy, 4 Hold, 0 Sell) yet sees only +6.9% upside to the average target, and the $300 low target sits below the current price, framing a balanced risk/reward. The pivotal variable is whether the AI data-center cooling and bioprocessing mix shift can sustain double-digit growth and high-teens margins long enough to grow into the multiple; if it can, the stock compounds, but if foodservice softness or CoolIT integration friction slows growth toward mid-single digits, the multiple has room to compress toward its low-30s historical median. I would upgrade to bullish on a pullback toward the $280s (roughly 30x forward EPS) or on evidence of sustained high-teens operating margins with organic growth above 8%, and downgrade to bearish if organic growth fell below 5% or CoolIT integration slipped.

Historical Price
Current Price $294.70
Average Target $326.50
High Target $360.00
Low Target $243.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Ecolab's 12-month outlook, with a consensus price target around $342.95 and implied upside of +16.4% versus the current price.

Average Target

$342.95

24 analysts

Implied Upside

+16.4%

vs. current price

Analyst Count

24

covering this stock

Price Range

$310 - $385

Analyst target range

Buy
22 (92%)
Hold
2 (8%)
Sell
0 (0%)

Coverage is deep and overwhelmingly constructive: 21 analysts cover Ecolab with 20 Buy/Overweight ratings, 4 Hold, and zero Sells, yielding a consensus recommendation of "buy" and a recommendation mean of 1.54 (where 1.0 is a strong buy). The average target price of $330.57 implies roughly +6.9% upside from the current $309.27, a modest but positive expected return that reflects how much of the bull case is already embedded in the price after the stock's 18% one-year run. The consensus leans clearly bullish on direction but only moderately so on near-term upside, suggesting analysts see the stock as a high-quality core holding rather than a mispriced opportunity at current levels. The target range spans $300 to $360, a spread of about 20% around the average, which signals moderate — not extreme — disagreement among analysts. The $360 high target likely assumes successful CoolIT integration, accelerating data-center cooling and bioprocessing revenue, continued operating-margin expansion toward the high-teens, and multiple maintenance or modest expansion on a premium-quality franchise; the $300 low target effectively prices in flat-to-modest upside and reflects caution on restaurant/foodservice softness, acquisition integration risk, and the possibility of multiple compression from an already-rich 35.8x PE. Institutional ratings show a stable-to-improving pattern — Oppenheimer upgraded to Outperform from Perform on July 17, 2026, and UBS, JPMorgan, Citigroup, Mizuho, and BMO have reiterated Buy/Overweight/Outperform ratings around the Q2 and Q3 prints, with Wells Fargo the lone Equal Weight holdout — indicating no meaningful downgrade cycle and reinforcing the view that the analyst community is aligned on the quality of the franchise even as the stock approaches consensus fair value.

Drowning in data?

Find the real signal!

Bulls vs Bears: ECL Investment Factors

The bull case currently carries stronger evidence: revenue is re-accelerating at 12.72% YoY, operating margin has expanded 196 basis points from Q1 to Q3 2026, free cash flow of $1.795B comfortably covers the dividend, and the stock is posting +22.77 points of six-month relative strength against a falling market with zero sell ratings from 21 analysts. The bear case is not about business quality but about price — a 35.8x trailing PE, 7.61x book, and only +6.9% implied upside to the $330.57 average target mean the market has already paid for the CoolIT and bioprocessing pivot. The single most important tension is whether the AI data-center cooling and life-sciences mix shift can sustain double-digit growth and high-teens operating margins long enough to grow into the premium multiple; if it can, the stock compounds, but if foodservice softness or CoolIT integration friction slows growth back toward mid-single digits, the multiple has room to compress toward its low-30s historical median. On balance, the fundamentals support a constructive but valuation-constrained view — a high-quality core holding rather than a mispriced opportunity at $309.27.

Bullish

  • Revenue re-accelerating to 12.7% YoY: Q3 2026 revenue of $4.695B rose 12.72% versus $4.165B in Q3 2025, well above Ecolab's historical mid-single-digit organic trajectory. The sequential cadence ($4.066B Q1, $4.415B Q2, $4.695B Q3) shows steady quarter-over-quarter expansion, indicating the CoolIT acquisition and pricing are adding real top-line momentum rather than a one-off bump.
  • Operating margin stepping up on mix shift: Operating margin climbed from 15.30% in Q1 2026 to 17.26% in Q3 2026 while gross margin held stable in the 43.5%–44.1% band, evidence of genuine operating leverage as higher-margin data-center cooling and life-sciences revenue scales. This is exactly the margin profile a mix-shift story should produce, and it validates management's pivot narrative.
  • Overwhelming analyst consensus, zero sells: 21 analysts cover ECL with 20 Buy/Overweight ratings, 4 Hold, and zero Sells, yielding a recommendation mean of 1.54 and a consensus 'buy'. The average target of $330.57 implies +6.9% upside from $309.27, and the stable-to-improving rating pattern (Oppenheimer upgrade July 2026, UBS/JPMorgan/Citi/Mizuho/BMO reiterations) shows no downgrade cycle forming.
  • Market-beating relative strength in weak tape: ECL gained 7.49% over the past month and 12.01% over three months while the S&P 500 fell 2.26% and 2.83% respectively, producing +9.75 and +14.84 points of relative strength. The 24.90% six-month gain versus SPY's 2.13% (+22.77 points) confirms durable idiosyncratic accumulation rather than a beta-driven bounce, with beta at just 0.857.

Bearish

  • Premium valuation leaves no room for error: At 35.8x trailing and 32.9x forward earnings, 24.0x EV/EBITDA, and 5.76x EV/Sales, ECL trades at roughly a 50–70% premium to specialty-chemical peers in the high-teens to low-20s PE range. Price-to-book of 7.61x versus a sector norm of 2–3x underscores how much of the valuation rests on intangibles, so any execution stumble could trigger sharp multiple compression.
  • CoolIT integration and balance-sheet strain: The $4.75B CoolIT acquisition drove $4.656B of Q3 acquisition outlays, a $4.413B net cash decline, and required financing, pushing debt-to-equity to 0.965 with a current ratio of just 1.076. Interest coverage of roughly 6.5x is adequate but not fortress-like, and integration missteps on a deal this size would hit both earnings and the premium multiple.
  • Foodservice softness caps near-term growth: Softer restaurant/foodservice traffic is an explicit near-term headwind for Global Institutional, the second-largest segment at $1.638B in Q3. Because the 12.7% growth rate already embeds acquisition contribution, deceleration in this cyclical end-market raises the bar for organic execution and could disappoint investors extrapolating the current trajectory.
  • Modest analyst upside signals fair value: The average target of $330.57 implies only +6.9% upside, and the low target of $300 sits below the current $309.27 price, meaning the most cautious analyst sees downside. With the stock at roughly 87% of its 52-week range and just 3.0% below the $318.93 high, much of the bull case appears already embedded after the 18% one-year run.

ECL Technical Analysis

Ecolab is in a sustained, well-established uptrend: the stock is up 18.05% over the trailing year and 17.75% year-to-date, and at $309.27 it trades at roughly 87% of its 52-week range (low $243.15, high $318.93), just 3.0% below the 52-week high. That positioning signals persistent institutional accumulation and momentum leadership rather than a value or falling-knife setup, though proximity to the highs also raises the risk of near-term overextension and profit-taking. The stock's max drawdown of -20.31% over the period shows it is not immune to sharp corrections, so the current strength should be read as trend confirmation rather than a low-risk entry point. Short-term momentum is decisively positive and accelerating: ECL gained 7.49% over the past month and 12.01% over three months, with the one-month move outpacing the three-month and one-year figures, indicating an inflection higher rather than deceleration. Critically, this momentum is occurring against a weak tape — the S&P 500 fell 2.26% over the past month and 2.83% over three months — producing relative strength of +9.75 percentage points over one month and +14.84 points over three months, one of the strongest readings in the dataset. The 24.90% six-month gain versus SPY's 2.13% (+22.77 points of relative strength) confirms a durable, market-beating trend rather than a beta-driven bounce. Key technical levels are the $318.93 52-week high as immediate resistance and the $243.15 52-week low as the structural floor, with the $300 round-number area now acting as near-term support after the recent breakout above it. A decisive break above $318.93 would confirm trend continuation and likely invite momentum and trend-following flows, while a failure and breakdown below $300 would flag exhaustion and open the door to a retest of the low-$280s. With a beta of 0.857, Ecolab is roughly 14% less volatile than the market, which supports larger position sizing for a given risk budget but also means the stock's outperformance is being driven by idiosyncratic, company-specific strength rather than leverage to market beta.

Beta

0.86

0.86x market volatility

Max Drawdown

-20.3%

Largest decline past year

52-Week Range

$243-$319

Price range past year

Annual Return

+12.6%

Cumulative gain past year

PeriodECL ReturnS&P 500
1m+2.3%-9.7%
3m+4.6%-9.9%
6m+16.3%-7.5%
1y+12.6%+4.7%
ytd+12.2%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

ECL Fundamental Analysis

Revenue is growing at a healthy and re-accelerating pace: Q3 2026 revenue of $4.695 billion rose 12.72% year-over-year versus $4.165 billion in Q3 2025, and the sequential cadence ($4.066B in Q1, $4.415B in Q2, $4.695B in Q3) shows steady quarter-over-quarter expansion. Segment data points to Water Services as the largest contributor at $2.481 billion, followed by Global Institutional at $1.638 billion, with Pest Elimination ($364 million) and Global Healthcare and Life Sciences ($216 million) rounding out the mix — the latter two being the smaller but strategically important high-growth adjacencies tied to data-center cooling and bioprocessing. The 12.7% top-line growth, well above Ecolab's historical mid-single-digit organic trajectory, implies acquisitions (notably CoolIT) and pricing are contributing meaningfully, which supports the bull case but also raises the bar for organic execution. Profitability is solid and improving: Q3 2026 net income was $551.3 million on a 44.08% gross margin, with operating income of $810.5 million (17.26% operating margin) and a 11.74% net margin. Gross margin has been remarkably stable in the 43.5%–44.1% band across the last four quarters (Q1 43.55%, Q2 44.07%, Q3 44.08%), while operating margin has stepped up from 15.30% in Q1 to 17.26% in Q3, evidence of operating leverage as revenue scales. The company is comfortably profitable with a 21.24% ROE and 7.29% ROA, and the margin trajectory — stable gross, expanding operating — is exactly the profile investors want to see from a mix-shift story toward higher-margin data-center and life-sciences offerings. The balance sheet carries moderate leverage: debt-to-equity of 0.965 and a current ratio of 1.076, with interest coverage of roughly 6.5x in the most recent quarter, adequate but not fortress-like. Free cash flow is robust at $1.795 billion TTM, and Q3 operating cash flow of $763.7 million comfortably funded $313.4 million of capex (FCF of $450.3 million) plus $204.6 million of dividends, though the quarter's $4.656 billion of acquisition outlays drove a $4.413 billion net cash decline and required financing. The dividend is well covered with a payout ratio of 36.3% and a 1.01% yield, and the FCF yield of roughly 2.4% on the $74.4 billion market cap is modest — consistent with a premium-quality compounder rather than a deep-value cash-flow story.

Quarterly Revenue

$4.7B

2026-09

Revenue YoY Growth

+12.7%

YoY Comparison

Gross Margin

44.1%

Latest Quarter

Free Cash Flow

$1.8B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Global Healthcare And Life Sciences
Global Institutional
Global Pest Elimination
Water Services

Open an Account, get $2 TSLA now!

Valuation Analysis: Is ECL Overvalued?

Because Ecolab is solidly profitable (Q3 net income of $551.3 million; positive TTM earnings), the PE ratio is the appropriate primary metric. The stock trades at 35.8x trailing earnings versus 32.9x forward earnings, a roughly 8% compression that implies the market expects meaningful EPS growth — consistent with consensus 2027 EPS of $12.88 versus the current run-rate — but the modest trailing-to-forward gap suggests expectations are for steady compounding rather than explosive acceleration. The 24.0x EV/EBITDA and 5.76x EV/Sales multiples confirm the market is paying a premium for quality and mix-shift optionality. Against the specialty-chemicals industry, Ecolab's 35.8x trailing PE and 4.62x PS represent a substantial premium — specialty chemical peers typically trade in the high-teens to low-20s PE range, implying a premium of roughly 50–70% — and the 7.61x price-to-book versus a sector norm closer to 2–3x underscores how much of the valuation is intangible-driven (service model, customer entrenchment, brand). That premium is defensible on the basis of Ecolab's superior ROE (21.24% vs. typical sector mid-single-to-low-double digits), stable 44% gross margins, and its unique position as the share leader in a fragmented, service-intensive niche, but it leaves little room for execution missteps. On its own history, the current 35.8x trailing PE sits near the upper end of its multi-year band — historical quarterly PE readings ranged from roughly 24.6x to 50.5x, with the median in the low-to-mid 30s — and the 4.62x PS is toward the higher end of its historical 11x–19x range on a quarterly basis (noting the historical ps_ratio series appears computed on a different share/period basis, so directional comparison is more reliable than absolute). The PEG ratio of -26.6 is not meaningful given the sign convention and should be disregarded; the more useful signal is that the market is pricing in optimistic but not extreme expectations, leaving the stock fairly valued-to-rich with upside contingent on continued margin expansion and successful integration of the AI-cooling pivot.

PE

35.8x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 25x~50x

vs. Industry Avg

31.4x

Industry PE ~31.4x*

EV/EBITDA

24.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the balance sheet and the cost of the growth pivot. The $4.75B CoolIT acquisition drove $4.656B of Q3 acquisition outlays, a $4.413B net cash decline, and required financing, lifting debt-to-equity to 0.965 while the current ratio sits at a thin 1.076. Interest coverage of roughly 6.5x ($810.5M operating income against $124.8M quarterly interest expense) is adequate but leaves limited cushion if rates stay elevated, and the 35.8x trailing PE means the stock depends on continued EPS growth toward the $12.88 consensus 2027 estimate to justify its price. Revenue concentration adds a second layer: Water Services at $2.481B and Global Institutional at $1.638B together dominate the $4.695B quarterly top line, so a downturn in industrial or restaurant end-markets would hit the majority of revenue, while the high-growth adjacencies (Pest Elimination at $364M, Healthcare and Life Sciences at $216M) remain too small to offset a broad slowdown. Finally, the 12.72% growth rate embeds acquisition contribution, so any organic deceleration would be magnified in reported results. Market and competitive risks are dominated by valuation compression. At 35.8x trailing and 32.9x forward earnings, 24.0x EV/EBITDA, and 5.76x EV/Sales, ECL trades at roughly a 50–70% premium to specialty-chemical peers in the high-teens to low-20s PE range, and its 7.61x price-to-book versus a 2–3x sector norm means the multiple is supported by intangibles rather than tangible assets. With beta at 0.857 the stock is only ~14% less volatile than the market, so it is not a defensive hiding place if sector rotation hits premium-quality compounders; the recent news flow already shows this sensitivity, with the CoolIT announcement met by an immediate stock decline and weak technicals as investors questioned the price and timing. Competitive disruption in AI cooling is a real threat — data-center thermal management is attracting well-capitalized entrants — and softer restaurant/foodservice traffic remains a live cyclical drag on the Institutional segment. The worst-case scenario is a chain in which CoolIT integration disappoints, foodservice traffic deteriorates further, and growth decelerates toward mid-single digits just as the market reprices premium compounders lower. In that sequence, the multiple could compress from 35.8x toward its low-30s historical median or below, and the stock could retrace toward its 52-week low of $243.15 — a decline of roughly -21% from the current $309.27 — consistent with the -20.31% max drawdown already observed in the period. A more severe outcome, where the analyst low target of $300 is breached and momentum unwinds, could extend losses into the low-$280s or below, meaning an investor could realistically lose 20–25% from current levels in an adverse scenario.

FAQ

The most severe risk is valuation compression: at 35.8x trailing PE and 7.61x book versus a 2–3x sector norm, any growth disappointment could force the multiple toward its low-30s historical median, and the $300 low analyst target already sits below the $309.27 price. Second is balance-sheet and integration risk from the $4.75B CoolIT deal, which drove a $4.413B net cash decline and lifted debt-to-equity to 0.965 with a thin 1.076 current ratio and roughly 6.5x interest coverage. Third is end-market cyclicality — softer restaurant/foodservice traffic threatens the $1.638B Global Institutional segment, and Water Services at $2.481B means industrial softness would hit the majority of revenue. Fourth is competitive disruption in AI data-center thermal management, where well-capitalized entrants could pressure pricing and share in the very adjacency underpinning the bull case. Ranked by severity: valuation compression first, CoolIT integration second, end-market softness third, competitive disruption fourth.

The 12-month outlook is split into three scenarios. The base case (55% probability, $318–$335) assumes low-double-digit revenue growth with CoolIT contribution, operating margin holding at 17%–18%, and EPS tracking toward the $12.88 consensus, carrying the stock to the $330.57 average target (+6.9%). The bull case (25% probability, $345–$360) requires faster-than-expected AI-cooling and bioprocessing scaling, high-teens operating margins, and a sustained premium multiple, reaching the $360 high target. The bear case (20% probability, $243–$300) assumes CoolIT integration disappoints, foodservice deteriorates, and the multiple compresses toward the low-30s, taking the stock to the $300 low target or toward the $243.15 52-week low. The base case is most likely, hinging on the assumption that the premium multiple is roughly maintained rather than expanded as growth moderates from 12.72% toward high-single digits.

ECL screens as fairly valued to modestly rich rather than undervalued. At 35.8x trailing and 32.9x forward earnings, 24.0x EV/EBITDA, 5.76x EV/Sales, and 7.61x price-to-book, it trades at roughly a 50–70% premium to specialty-chemical peers in the high-teens to low-20s PE range. That premium is partly earned: ROE of 21.24% and stable 44% gross margins are well above typical sector norms, and the 35.8x trailing multiple sits near the upper end of its own historical band (roughly 24.6x to 50.5x, median in the low-to-mid 30s). The modest trailing-to-forward compression (35.8x to 32.9x) implies the market expects steady EPS growth toward the $12.88 consensus but not explosive acceleration. In short, the market is paying a quality premium and pricing in successful execution of the CoolIT and bioprocessing pivot — leaving limited margin for error.

From a risk/reward standpoint, ECL is a good business at a fair-to-full price rather than a compelling bargain. The bull case is well supported: revenue grew 12.72% YoY to $4.695B in Q3 2026, operating margin expanded from 15.30% in Q1 to 17.26% in Q3, free cash flow is $1.795B, and 20 of 21 analysts rate it Buy with zero Sells. But the average target of $330.57 implies only +6.9% upside from $309.27, and the $300 low target sits below the current price, meaning the most cautious analyst sees downside. The biggest downside risk is multiple compression from 35.8x trailing earnings toward the low-30s historical median if growth decelerates, which could take the stock toward the $243.15 52-week low, roughly -21%. It is a good buy for long-term investors seeking quality compounding who can tolerate a premium multiple, and a better buy on a pullback toward the $280s (about 30x forward EPS of $12.88).

ECL is best suited to long-term holding, with a suggested minimum horizon of two to three years. It is a mature, profitable compounder — 48,000 employees, a global market-share lead, 21.24% ROE, and $1.795B of TTM free cash flow — whose value accrues through steady EPS growth and a modest 1.01% dividend (36.3% payout) rather than through rapid multiple expansion, which is already elevated at 35.8x trailing earnings. Volatility is moderate with beta of 0.857, but the -20.31% max drawdown shows it can correct sharply, and its 24.90% six-month gain leaves it near 52-week highs, making it a poor candidate for momentum chasing. Short-term traders could work the $300 support and $318.93 resistance levels, but the durable case is a buy-and-hold core position that lets the CoolIT and bioprocessing mix shift compound margins and earnings over multiple years.